SCHEMBL2736793

SCHEMBL2736793

CCCCn1cc(-c2cc3ccccc3s2)cc(C(=O)NCCCN2CCOCC2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.57
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
HIF1A Q16665 1/20 0.45
BCL3 P20749 1/20 0.44
TACR2 P21452 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
TYRO3 Q06418 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736860 0.85 LMNA (0.56) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736803 0.84 LMNA (0.45) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736791 0.83 CNR2 (0.49) CD274ALDH1A1HSD17B10CNR1CNR2
SCHEMBL2736789 0.83 KDM4E (0.62) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736846 0.82 SMYD2 (0.54) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736790 0.81 CNR2 (0.52) ALDH1A1CNR1CNR2POLBMAPT
SCHEMBL2736855 0.81 SMN1; SMN2 (0.55) ALDH1A1HPGDTSHRCNR1CNR2
SCHEMBL2736818 0.81 TDP1 (0.54) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736865 0.81 CHEK1 (0.47) KDM4EALDH1A1HPGDTSHRMAOA
SCHEMBL2736851 0.81 TSHR (0.48) KDM4EALDH1A1HPGDTSHRMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CD274 1606/4885KDM4E 1679/4885ALDH1A1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.